| Current status of enhanced recovery after surgery (ERAS) protocol in gastrointestinal surgery |
33 |
| The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma |
28 |
| Immunotherapy in triple-negative breast cancer |
21 |
| Importance of m N-6-methyladenosine (m(6)A) RNA modification in cancer |
14 |
| Patient performance status and cancer immunotherapy efficacy: a meta-analysis |
11 |
| Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review |
10 |
| Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients |
10 |
| Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis |
9 |
| Real-world outcomes in patients with unresected stage III non-small cell lung cancer |
9 |
| Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer |
8 |
| Multicenter prospective study validating the efficacy of a quantitative assessment tool for frailty in patients with urological cancers |
8 |
| Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis |
8 |
| Interaction between phytotherapy and oral anticancer agents: prospective study and literature review |
8 |
| Hypofractionated postmastectomy radiotherapy with helical tomotherapy in patients with immediate breast reconstruction: dosimetric results and acute/intermediate toxicity evaluation |
8 |
| SOX4 is activated by C-MYC in prostate cancer |
8 |
| Circular RNA expression and circPTPRM promotes proliferation and migration in hepatocellular carcinoma |
8 |
| The Influence of Tumor Microenvironment on ATG4D Gene Expression in Colorectal Cancer Patients |
8 |
| Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score |
8 |
| Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study |
7 |
| Imaging of distant metastases of prostate cancer |
7 |
| De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients |
7 |
| Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis |
7 |
| Clinical and Histopathologic Correlates and Management Strategies for Inflammatory Myofibroblastic tumor of the lung. A case series and review of the literature |
7 |
| Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme |
7 |
| Check point inhibitors a new era in renal cell carcinoma treatment |
7 |
| A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes |
6 |
| Liver graft rejection following immune checkpoint inhibitors treatment: a review |
6 |
| Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer |
6 |
| Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer |
6 |
| Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors |
6 |
| Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma |
6 |
| Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment |
6 |
| Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization |
6 |
| The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma |
5 |
| Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells |
5 |
| Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment |
5 |
| Prospects of chimeric antigen receptor T cell therapy in ovarian cancer |
5 |
| Characteristics and impact of programmed death-ligand 1 expression, CD8+tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma |
5 |
| A feedback regulation of CREB activation through the CUL4A and ERK signaling |
5 |
| Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer |
5 |
| Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival |
5 |
| Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer |
5 |
| Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy |
4 |
| Stability of matrix metalloproteinase-9 as biological marker in colorectal cancer |
4 |
| Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma |
4 |
| Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elementsa clinicopathologic and genomic sequencing-based discussion |
4 |
| Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study |
4 |
| Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy |
4 |
| Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment |
4 |
| Sorafenib in patients with progressed and refractory bone tumors |
4 |
